Tirzepatide (40 mg) is a synthetic, long-acting peptide engineered as a dual incretin analog, structurally derived from gut hormones involved in metabolic regulation. It contains 39 amino acids, including non-standard substitutions and a lipid side chain, enhancing stability and receptor interaction in experimental systems. Its molecular formula is C₂₂₅H₃₄₈N₄₈O₆₈, with a molecular weight of 4813.48 g/mol.

Supplied as a high-purity lyophilized powder in a 40 mg vial, Tirzepatide supports higher-concentration stock solutions for extended or large-scale studies. Research primarily focuses on its role in energy balance, glucose metabolism, and hormonal signaling.

Tirzepatide (40 mg) Key Features & Specs

• Subcategory: Weight Loss & Metabolic Peptides
• Strength: 40 mg
• CAS: 2023788-19-2
• Chemical Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: 4813.48 g/mol
• Peptide Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20-linker)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
• Synonyms: P1206, LY3298176, tirzepatida, tirzepatidum, OYN3CCI6QE

For laboratory research use only.

Tirzepatide (40 mg) Research Uses

Tirzepatide is used to study the effect of dual incretin signaling on glucose control, appetite regulation, and energy utilization. In preclinical models, it evaluates pancreatic function, including insulin and glucagon secretion, and examines gastric emptying and nutrient absorption. Central nervous system studies explore its influence on appetite regulation and feeding behavior.

Research also focuses on lipid metabolism and adipose tissue biology, measuring fat distribution, lipid storage, and energy expenditure. Additional studies examine liver metabolism, hepatic fat accumulation, and metabolic stress responses.

Cell-based assays support mechanistic research by evaluating second-messenger signaling, hormone release, and cellular responses to metabolic stress. Tirzepatide is used as an investigational compound for studying integrated metabolic systems rather than as a therapeutic intervention.

Tirzepatide (40 mg) Insights & Observed Findings

• Animal Studies: Doses between 3 and 10 nmol/kg have been used in short-term experiments, with higher or repeated doses in chronic models. These studies observe changes in food intake, body weight, and glucose tolerance markers.
• Controlled Experiments: Some studies show metabolic improvements even when food intake is controlled, indicating additional systemic effects beyond caloric restriction.
• Mechanistic Studies: As a biased dual agonist, Tirzepatide may activate signaling pathways differently from native hormones. This characteristic is explored to understand how combined incretin signaling affects metabolic outcomes.

Overall, while consistent metabolic effects are observed in controlled settings, further investigation is required to fully characterize Tirzepatide’s biological activity.

Tirzepatide (40 mg) Handling & Storage

• Store Tirzepatide (40 mg) lyophilized at –20°C or below. Keep the vial sealed and protected from light and moisture to maintain peptide integrity.
• Allow the vial to reach room temperature before opening to reduce condensation. Reconstitute with a sterile aqueous solution using aseptic technique.
• Prepared solutions should be stored at 2–8°C for short-term use. Aliquoting is recommended to minimize repeated freeze-thaw exposure during experimental workflows.
• Handle all materials in accordance with standard laboratory protocols for peptide compounds.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. National Center for Biotechnology Information. PubChem Compound Summary for CID 156588324, Tirzepatide. https://pubchem.ncbi.nlm.nih.gov/compound/156588324
2. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
3. Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. doi:10.1073/pnas.2116506119
4. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
5. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. Published 2022 Jul 5. doi:10.3390/molecules27134315